Thomas Shrader (BTIG) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Thomas Shrader's stock ratings?

About 47% of Thomas's ratings were profitable over a one-year hold, with an average return of -0.7% per rating, measured by 13Foresight from historical prices.

Q: How is Thomas ranked?

Thomas Shrader is ranked #2498 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Thomas Shrader

BTIG

Thomas Shrader

BTIG

Wall Street Analyst

★☆☆☆☆

#2498

on 13Foresight · ranked by our own returns

47%

Success Rate

-0.7%

Average Return

28 of 59 calls profitable · -10532.4% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

🔒 5-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 47% of Thomas Shrader's ratings turned a profit when each position was held for 1 year — averaging -0.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

128 Buy 10 Hold 0 Sell

Thomas's Stock Coverage 66 ratings · 2026-06-21

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
IRD Opus Genetics	Jun 16, 2026	BUY	Strong Buy +154.5% avg upside 23 analysts	$12.00 194.79% Upside	·
IVVD Invivyd	Jun 11, 2026	BUY	Buy +734.3% avg upside 8 analysts	$10.00 931.01% Upside	+9.7%
NVAX Novavax	Jun 11, 2026	BUY	Buy +154.1% avg upside 20 analysts	$19.00 108.01% Upside	-1.7%
GANX Gain Therapeutics	May 26, 2026	BUY	Strong Buy +318.8% avg upside 9 analysts	$5.00 165.87% Upside	·
NTHI NeOnc Technologies Holdings, Inc.	May 26, 2026	BUY	Strong Buy +203.7% avg upside 3 analysts	$15.00 184.68% Upside	-9.7%
CMPS COMPASS Pathways	May 13, 2026	BUY	Strong Buy +63.6% avg upside 18 analysts	$14.00 11.73% Upside	+8.9%
BIOA BioAge Labs, Inc.	May 13, 2026	BUY	Strong Buy +138.3% avg upside 9 analysts	$40.00 92.67% Upside	-7.7%
ANRO Alto Neuroscience, Inc.	May 13, 2026	BUY	Strong Buy +33.3% avg upside 13 analysts	$28.00 23.05% Upside	-7.3%
HROW Harrow Health	May 12, 2026	BUY	Strong Buy +25.2% avg upside 12 analysts	$63.00 46.93% Upside	+44.5%
DNLI Denali Therapeutics	May 11, 2026	BUY	Strong Buy +60.2% avg upside 24 analysts	$39.00 67.28% Upside	+11.5%
STOK Stoke Therapeutics	May 11, 2026	BUY	Strong Buy +25.1% avg upside 18 analysts	$39.00 25.83% Upside	-8.1%
BIIB Biogen	Apr 20, 2026	HOLD	Strong Buy +25.1% avg upside 51 analysts	—	+8.4%
ABOS Acumen Pharmaceuticals	Apr 02, 2026	BUY	Strong Buy +258.9% avg upside 10 analysts	$8.00 253.98% Upside	-13.0%
ALEC Alector	Apr 02, 2026	BUY	Hold +532.1% avg upside 14 analysts	$6.00 242.88% Upside	-10.4%
DRUG Bright Minds Biosciences	Mar 30, 2026	BUY	Strong Buy +120.9% avg upside 10 analysts	$147.00 142.34% Upside	+22.0%
OVID Ovid Therapeutics	Mar 26, 2026	BUY	Strong Buy +109.1% avg upside 17 analysts	$4.00 76.26% Upside	+6.9%
NRXP NRX Pharmaceuticals	Mar 24, 2026	BUY	Strong Buy +912.6% avg upside 5 analysts	$25.00 529.75% Upside	+80.3%
ALDX Aldeyra Therapeutics	Mar 17, 2026	BUY	Strong Buy +713.6% avg upside 21 analysts	$9.00 359.12% Upside	+35.5%
COYA Coya Therapeutics, Inc.	Mar 16, 2026	BUY	Strong Buy +225.2% avg upside 7 analysts	$16.00 225.22% Upside	+3.8%
ACIU AC Immune SA	Mar 16, 2026	BUY	Strong Buy +233.3% avg upside 5 analysts	$8.00 233.32% Upside	-10.9%
ARCT Arcturus Therapeutics	Mar 03, 2026	BUY	Buy +290.9% avg upside 35 analysts	$23.00 205.50% Upside	+6.2%
PCVX Vaxcyte	Mar 02, 2026	BUY	Strong Buy +96.1% avg upside 15 analysts	$89.00 72.95% Upside	-17.0%
BHVN Biohaven Ltd.	Nov 17, 2025	BUY	Strong Buy +87.5% avg upside 25 analysts	$16.00 17.86% Upside	+64.1%
INMB Inmune Bio	Nov 03, 2025	HOLD	Buy +753.2% avg upside 11 analysts	—	-31.1%
PMN ProMIS Neurosciences	Jul 21, 2025	BUY	Strong Buy +583.1% avg upside 6 analysts	$200.00 1797.52% Upside	-61.4%
IMDX Insight Molecular Diagnostics	May 13, 2025	HOLD	Buy -1.2% avg upside 10 analysts	—	·
ESPR Esperion	Mar 04, 2025	BUY	Buy +701.2% avg upside 22 analysts	$9.00 185.66% Upside	+64.4%
LONA LeonaBio	Mar 02, 2025	HOLD	Buy +13.9% avg upside 9 analysts	—	+52.1%
SEELQ Seelos Therapeutics	Mar 19, 2024	BUY	Buy +46385614.3% avg upside 10 analysts	$32.00 31999900.02% Upside	-100.0%
PLRX Pliant Therapeutics	Feb 28, 2024	BUY	Buy +1821.1% avg upside 21 analysts	$33.00 2744.86% Upside	-79.3%
CELU Celularity	Jan 05, 2024	BUY	Strong Buy +1938.2% avg upside 6 analysts	—	-6.1%
BBIO BridgeBio Pharma	Nov 17, 2023	HOLD	Strong Buy +38.7% avg upside 34 analysts	—	-18.9%
SLN Silence Therapeutics	Nov 14, 2023	BUY	Strong Buy +372.0% avg upside 9 analysts	$15.00 116.38% Upside	+51.6%
ANNX Annexon Biosciences	Aug 04, 2023	HOLD	Strong Buy +181.2% avg upside 13 analysts	—	+76.6%
SQZB SQZ Biotechnologies	May 05, 2023	HOLD	Buy +102677.8% avg upside 7 analysts	—	·
NERV Minerva Neurosciences	May 05, 2023	HOLD	Buy +67.8% avg upside 8 analysts	—	-60.5%
QTTB Q32 Bio	Apr 03, 2023	BUY	Strong Buy +345.2% avg upside 24 analysts	$216.00 1715.10% Upside	+18.3%
BCAB BioAtla	Mar 27, 2023	BUY	Strong Buy +2518.3% avg upside 13 analysts	$13.00 255.63% Upside	+39.0%
MGNX MacroGenics	Mar 20, 2023	BUY	Strong Buy +326.2% avg upside 25 analysts	$12.00 190.63% Upside	+130.0%
NUVB Nuvation Bio	Mar 20, 2023	HOLD	Strong Buy +132.2% avg upside 15 analysts	—	+15.0%
CGEM Cullinan Management	Mar 12, 2023	BUY	Strong Buy +125.7% avg upside 15 analysts	$20.00 33.04% Upside	+54.0%
XNCR Xencor	Mar 05, 2023	BUY	Buy +159.9% avg upside 27 analysts	$56.00 342.95% Upside	-28.3%
RCUS Arcus Biosciences	Mar 02, 2023	BUY	Strong Buy +38.0% avg upside 20 analysts	$70.00 187.94% Upside	+8.7%
CUE Cue Biopharma	Oct 15, 2021	HOLD	Strong Buy -66.9% avg upside 9 analysts	—	-79.6%
IMVIF IMV	Oct 15, 2021	HOLD	Buy +2443368900.1% avg upside 7 analysts	—	·
SYBX Synlogic	Oct 15, 2021	HOLD	Buy +3290.3% avg upside 11 analysts	—	-61.1%
DTIL Precision BioSciences	Sep 09, 2021	BUY	Strong Buy +247.1% avg upside 12 analysts	$16.00 135.05% Upside	-87.2%
REPL Replimune Group	Aug 06, 2021	BUY	Hold +72.3% avg upside 13 analysts	$60.00 488.87% Upside	-37.0%
ONCSQ OncoSec Medical	Jul 06, 2021	BUY	Strong Buy +4699999900.0% avg upside 9 analysts	$10.00 999999900.02% Upside	·
LITS Lite Strategy	Jun 10, 2021	BUY	Strong Buy +1215.4% avg upside 13 analysts	$5.50 564.44% Upside	·
GERN Geron	Jun 04, 2021	HOLD	Strong Buy +239.8% avg upside 19 analysts	—	-0.7%
VYGR Voyager Therapeutics	May 10, 2021	HOLD	Strong Buy +284.2% avg upside 23 analysts	—	+47.2%
VCNX Vaccinex	Sep 23, 2020	HOLD	Buy +530.7% avg upside 2 analysts	—	·
STRO Sutro Biopharma	Oct 06, 2019	BUY	Strong Buy +31.6% avg upside 20 analysts	—	+19.5%
PGEN Precigen	Nov 09, 2017	BUY	Buy +404.8% avg upside 11 analysts	$39.00 709.12% Upside	·
RNAC Cartesian Therapeutics	Nov 07, 2017	BUY	Strong Buy +228.2% avg upside 19 analysts	$26.00 169.99% Upside	-44.0%
VTVT vTv Therapeutics	Nov 01, 2017	BUY	Strong Buy -6.9% avg upside 12 analysts	$12.00 65.79% Downside	-56.5%
HCM HUTCHMED	Oct 17, 2017	BUY	Strong Buy +208.7% avg upside 9 analysts	$40.00 289.05% Upside	+3.8%
ANAB AnaptysBio	Oct 10, 2017	BUY	Strong Buy +26.1% avg upside 26 analysts	$76.00 32.16% Upside	+17.9%
INO Inovio Pharmaceuticals	Oct 05, 2017	BUY	Strong Buy +808.3% avg upside 19 analysts	$11.00 886.63% Upside	-17.7%
PBYI Puma Biotechnology	Oct 02, 2017	BUY	Hold +458.2% avg upside 11 analysts	$130.00 1619.63% Upside	-61.0%
FBRX Forte Biosciences	Jul 24, 2017	BUY	Strong Buy +128.0% avg upside 14 analysts	$24.00 34.41% Upside	-14.2%
WINT Windtree Therapeutics	Jun 30, 2017	HOLD	Strong Buy +40610.2% avg upside 6 analysts	$6.00 35214.98% Upside	·
KYNB Kyntra Bio	Jun 21, 2017	BUY	Buy +370.8% avg upside 14 analysts	$38.00 467.18% Upside	+103.8%
ELDN Eledon Pharmaceuticals	Dec 22, 2016	HOLD	Buy +302.0% avg upside 10 analysts	$10.80 175.44% Upside	-64.5%
GILD Gilead Sciences	Mar 23, 2015	HOLD	Strong Buy -4.8% avg upside 66 analysts	—	-8.6%

🔒 61 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Thomas Shrader — Frequently Asked Questions

How accurate are Thomas Shrader's stock ratings?

Based on the calls 13Foresight could measure, about 47% of Thomas's ratings were profitable over a one-year hold, with an average return of -0.7% per rating, or -10532.5% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Thomas ranked on 13Foresight?

Thomas Shrader is currently ranked #2498 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Thomas cover?

Thomas most recently has ratings on IRD, IVVD, NVAX, GANX, NTHI, CMPS, BIOA, ANRO, HROW, DNLI, STOK, BIIB and 54 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!